Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
Jeffrey A. Cohen(Cleveland Clinic), Ludwig Kappos(University Hospital of Basel), Philipp von Rosenstiel(Biogen (United States)), Davorka Tomic(Multiple Sclerosis Research Institute), Tracy Stites, Jean Pelletier(Hôpital de la Timone), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Bhupendra Khatri(Hope Center for Neurological Disorders), Giancarlo Comi(Vita-Salute San Raffaele University), Shannon Ritter(Novartis (United States)), Hans-Peter Hartung(The University of Sydney), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya)
Cited by 163
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k